View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Comment
June 9, 2021

LoA Update: AstraZeneca’s AZD2811 approval chances in refractory acute myeloid leukaemia decrease by one point after Phase I/II trial listed as completed

AstraZeneca’s AZD2811 in refractory acute myeloid leukaemia had its Likelihood of Approval (LoA) drop by one point on the heels of its Phase I/II ClinicalTrials.gov listing, updated as completed on 27 May.

By Reynald Castañeda

AstraZeneca’s AZD2811 in refractory acute myeloid leukaemia had its Likelihood of Approval (LoA) drop by one point on the heels of its Phase I/II ClinicalTrials.gov listing, updated as completed on 27 May. AZD2811’s Phase Transition Success Rate (PTSR) also dropped by five points from 9%, as of 1 June. The asset previously had an LoA of 3%, decreasing to 2%.

The 50-patient Phase I/II trial was investigating the maximum tolerated dose, safety, pharmacokinetics, and pharmacokinetics of AZD2111 as a monotherapy or in combination with various agents, as per ClinicalTrials.gov. AZD2811 is a nanoparticle which is a selective inhibitor of aurora B kinase.

LoA is identified via GlobalData’s analysis using a combination of machine learning and its proprietary algorithm. LoA is calculated by compounding the PTSR at each stage the drug is yet to progress through. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next. Both LoA and PTSR can be calculated for a drug by considering characteristics like therapy area, indication and molecule type.

AstraZeneca has a market cap of $148.34bn.

Reynald Castaneda is an Associate Editor for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena